FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried

August 7, 2014 by Arezu Sarvestani

Despite the furor on Capitol Hill, lawmakers aren't likely to produce reform that will hinder Medtronic's $43 billion acquisition of Covidien, according to Morgan Stanley analysts.

Analyst report: Dems can't stop Medtronic-Covidien merger

Get the complete picture with a MassDevice Plus membership. Registered users can login here.